Ondansetron
- Generic Name
- Ondansetron
- Brand Names
- Zofran, Zuplenz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O
- CAS Number
- 99614-02-5
- Unique Ingredient Identifier
- 4AF302ESOS
- Background
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...
- Indication
In the adult patient population:
i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:
- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum
- Associated Therapies
- -
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
- Conditions
- Interventions
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT00954941
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT00934180
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States
Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT00934921
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States
Role of Anti-Inflammatory Agents in Patients With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Pakistan Institute of Living and Learning
- Target Recruit Count
- 36
- Registration Number
- NCT00929955
- Locations
- 🇵🇰
Dow University of Health Sciences, Karachi, Pakistan
🇵🇰Karwan e hayat, Karachi, Pakistan
Bioavailability Study of Anti Nausea Medication With and Without Food
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 22
- Registration Number
- NCT00905190
- Locations
- 🇨🇦
Algorithme Pharma INc., Mount-Royal, Quebec, Canada
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00891761
- Locations
- 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
- Conditions
- Interventions
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 74
- Registration Number
- NCT00890149
- Locations
- 🇺🇸
Clinical Neurobehavioral Center, Columbia, Maryland, United States
Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy
- Conditions
- Interventions
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Hospital for Special Surgery, New York
- Target Recruit Count
- 98
- Registration Number
- NCT00878228
- Locations
- 🇺🇸
Hospital for Special Surgery, New York, New York, United States
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
- Conditions
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 81
- Registration Number
- NCT00871910
Dexamethasone for Postoperative Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- University of Jordan
- Target Recruit Count
- 180
- Registration Number
- NCT00825071
- Locations
- 🇯🇴
Jordan University Hospital, Amman, Jordan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.